Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

J. Pigozzo · SciRah

Researcher profile · Semantic Scholar

J. Pigozzo

Share profile

J. Pigozzo — researcher profile on SciRah

h-index: 28
Works: 104
Citations: 3,118

Most-cited papers

Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial
C. Lebbé, N. Meyer, L. Mortier, I. Márquez-Rodas +15 more
2019Journal of Clinical Oncology320 citations Open access
Semantic Scholar
Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab.
P. Ferrucci, P. Ascierto, J. Pigozzo, M. Del Vecchio +14 more
2016Annals of Oncology246 citations Open access
Semantic Scholar
Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab.
P. Ferrucci, P. Ascierto, J. Pigozzo, M. Del Vecchio +14 more
2016Annals of Oncology197 citations Open access
Semantic Scholar
Sex and interleukin-6 are prognostic factors for autoimmune toxicity following treatment with anti-CTLA4 blockade
S. Valpione, S. Pasquali, L. Campana, L. Piccin +3 more
2018Journal of Translational Medicine184 citations Open access
Semantic Scholar
Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort
P. Ascierto, E. Simeone, V. C. Sileni, J. Pigozzo +16 more
2014Journal of Translational Medicine165 citations Open access
Semantic Scholar
Efficacy and safety of ipilimumab 3mg/kg in patients with pretreated, metastatic, mucosal melanoma.
M. Del Vecchio, L. Di Guardo, P. Ascierto, A. Grimaldi +14 more
2014European Journal of Cancer150 citations Open access
Semantic Scholar
Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanoma.
Michele Maio, R. Danielli, V. Chiarion-Sileni, J. Pigozzo +13 more
2013Annals of Oncology149 citations Open access
Semantic Scholar
Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915)
J. Weber, D. Schadendorf, M. Del Vecchio, J. Larkin +32 more
2022Journal of Clinical Oncology140 citations Open access
Semantic Scholar
Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases
P. Queirolo, F. Spagnolo, P. Ascierto, E. Simeone +14 more
2014Journal of Neuro-Oncology118 citations Open access
Semantic Scholar
Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme
Vanna Chiarion Sileni, J. Pigozzo, P. Ascierto, A. Grimaldi +16 more
2014Journal of experimental & clinical cancer research : CR106 citations Open access
Semantic Scholar
Cobimetinib plus atezolizumab in BRAFV600 wild-type melanoma: primary results from the randomized phase 3 IMspire170 study.
H. Gogas, B. Dréno, J. Larkin, L. Demidov +16 more
2020Annals of Oncology86 citations Open access
Semantic Scholar
Ipilimumab retreatment in patients with pretreated advanced melanoma: the expanded access programme in Italy
V. Chiarion-Sileni, J. Pigozzo, P. Ascierto, E. Simeone +13 more
2014British Journal of Cancer64 citations Open access
Semantic Scholar
Central nervous system failure in melanoma patients: results of a randomised, multicentre phase 3 study of temozolomide- and dacarbazine- based regimens
V. Chiarion-Sileni, Michele Guida, L. Ridolfi, Antonella Romanini +6 more
2011British Journal of Cancer60 citations Open access
Semantic Scholar
Body mass index (BMI) and outcome of metastatic melanoma patients receiving targeted therapy and immunotherapy: a multicenter international retrospective study
P. Rutkowski, A. Indini, Matilde De Luca, B. Merelli +14 more
2020Journal for ImmunoTherapy of Cancer57 citations Open access
Semantic Scholar
Clinical implication of tumor-associated and immunological parameters in melanoma patients treated with ipilimumab
V. Damuzzo, S. Solito, L. Pinton, E. Carrozzo +5 more
2016Oncoimmunology57 citations Open access
Semantic Scholar
Mitotic rate correlates with sentinel lymph node status and outcome in cutaneous melanoma greater than 1 millimeter in thickness: A multi‐institutional study of 1524 cases
M. Mandalà, F. Galli, L. Cattaneo, B. Merelli +14 more
2017Journal of American Academy of Dermatology48 citations
Semantic Scholar
Personalised medicine: Development and external validation of a prognostic model for metastatic melanoma patients treated with ipilimumab.
S. Valpione, C. Martinoli, P. Fava, Simone Mocellin +7 more
2015European Journal of Cancer48 citations Open access
Semantic Scholar
Development and External Validation of a Prognostic Nomogram for Metastatic Uveal Melanoma
S. Valpione, J. Moser, R. Parrozzani, Marco Bazzi +8 more
2015PLoS ONE44 citations Open access
Semantic Scholar
A retrospective analysis of 141 patients with liver metastases from uveal melanoma: a two-cohort study comparing transarterial chemoembolization with CPT-11 charged microbeads and historical treatments
S. Valpione, C. Aliberti, R. Parrozzani, Marco Bazzi +5 more
2015Melanoma research42 citations Open access
Semantic Scholar
Phase II trial of docetaxel, cisplatin and fluorouracil followed by carboplatin and radiotherapy in locally advanced oesophageal cancer
V. Chiarion-Sileni, L. Corti, Alberto Ruol, R. Innocente +6 more
2007British Journal of Cancer42 citations Open access
Semantic Scholar
The immune cell landscape of metastatic uveal melanoma correlates with overall survival
A. Tosi, R. Cappellesso, A. D. Dei Tos, V. Rossi +8 more
2021Journal of experimental & clinical cancer research : CR37 citations Open access
Semantic Scholar
Basal and one-month differed neutrophil, lymphocyte and platelet values and their ratios strongly predict the efficacy of checkpoint inhibitors immunotherapy in patients with advanced BRAF wild-type melanoma
M. Guida, N. Bartolomeo, D. Quaresmini, P. Quaglino +16 more
2022Journal of Translational Medicine34 citations Open access
Semantic Scholar
Anti-PD1 antibodies in patients aged ≥ 75 years with metastatic melanoma: A retrospective multicentre study.
L. Ridolfi, F. De Rosa, E. Petracci, E. Tanda +17 more
2020Journal of Geriatric Oncology34 citations
Semantic Scholar
Abstract CT004: Adjuvant therapy with nivolumab (NIVO) combined with ipilimumab (IPI) vs NIVO alone in patients (pts) with resected stage IIIB-D/IV melanoma (CheckMate 915)
G. Long, D. Schadendorf, M. Del Vecchio, J. Larkin +29 more
2021Clinical Trials31 citations
Semantic Scholar
No Impact of NRAS Mutation on Features of Primary and Metastatic Melanoma or on Outcomes of Checkpoint Inhibitor Immunotherapy: An Italian Melanoma Intergroup (IMI) Study
M. Guida, N. Bartolomeo, P. Quaglino, G. Madonna +15 more
2021Cancers31 citations Open access
Semantic Scholar
The cost of unresectable stage III or stage IV melanoma in Italy
M. Maio, P. Ascierto, A. Testori, R. Ridolfi +12 more
2012Journal of experimental & clinical cancer research : CR30 citations Open access
Semantic Scholar
BRAF Gene Copy Number and Mutant Allele Frequency Correlate with Time to Progression in Metastatic Melanoma Patients Treated with MAPK Inhibitors
Camilla Stagni, Carolina Zamuner, L. Elefanti, Tiziana Zanin +9 more
2018Molecular Cancer Therapeutics28 citations
Semantic Scholar
Impact of BRAF mutation and BRAF inhibition on melanoma brain metastases
Tulasi Gummadi, B. Zhang, S. Valpione, Chul Kim +6 more
2015Melanoma research27 citations
Semantic Scholar
Combination treatment with cobimetinib (C) and atezolizumab (A) vs pembrolizumab (P) in previously untreated patients (pts) with BRAFV600 wild type (wt) advanced melanoma: Primary analysis from the phase III IMspire170 trial
A. Arance, H. Gogas, B. Dréno, K. Flaherty +13 more
2019Annals of Oncology26 citations Open access
Semantic Scholar
Consolidation electrochemotherapy with bleomycin in metastatic melanoma during treatment with dabrafenib
S. Valpione, L. Campana, J. Pigozzo, V. Chiarion-Sileni
2015Radiology and Oncology26 citations Open access
Semantic Scholar
A multiparameter liquid biopsy approach allows to track melanoma dynamics and identify early treatment resistance
M. Scaini, C. Catoni, C. Poggiana, J. Pigozzo +13 more
2024npj Precision Oncology25 citations Open access
Semantic Scholar
Multi-center phase II trial of chemo-radiotherapy with 5-fluorouracil, leucovorin and oxaliplatin in locally advanced esophageal cancer
V. Chiarion-Sileni, R. Innocente, R. Cavina, A. Ruol +6 more
2009Cancer Chemotherapy and Pharmacology25 citations Open access
Semantic Scholar
Two dosing regimens of nivolumab (NIVO) plus ipilimumab (IPI) for advanced (adv) melanoma: Three-year results of CheckMate 511.
C. Lebbé, N. Meyer, L. Mortier, I. Márquez-Rodas +14 more
202123 citations
Semantic Scholar
Molecular Basis of BRAF Inhibitor Resistance in Melanoma: A Systematic Review
I. Cosci, V. Salizzato, P. Del Fiore, J. Pigozzo +6 more
2025Pharmaceuticals22 citations Open access
Semantic Scholar
An Italian Retrospective Survey on Bone Metastasis in Melanoma: Impact of Immunotherapy and Radiotherapy on Survival
F. Mannavola, M. Mandalà, A. Todisco, V. C. Sileni +29 more
2020Frontiers in Oncology21 citations Open access
Semantic Scholar
Intensified high-dose intravenous interferon alpha 2b (IFNa2b) for adjuvant treatment of stage III melanoma: A randomized phase III Italian Melanoma Intergroup (IMI) trial [ISRCTN75125874].
V. Chiarion-Sileni, M. Guida, A. Romanini, R. Ridolfi +10 more
2011Journal of Clinical Oncology21 citations
Semantic Scholar
Nivolumab for Resected Stage III or IV Melanoma at 9 Years.
P. Ascierto, M. Del Vecchio, B. Merelli, H. Gogas +25 more
2025New England Journal of Medicine20 citations Open access
Semantic Scholar
Prognostic Factors in Merkel Cell Carcinoma: A Retrospective Single-Center Study in 90 Patients
M. Rastrelli, B. Ferrazzi, F. Cavallin, Vanna Chiarion Sileni +9 more
2018Cancers20 citations Open access
Semantic Scholar
Melanoma m1: diagnosis and therapy.
M. Rastrelli, S. Tropea, J. Pigozzo, E. Bezzon +4 more
2014In Vivo20 citations
Semantic Scholar
Discontinuation of anti-PD1 in advanced melanoma: an observational retrospective study from the Italian Melanoma Intergroup.
M. Rubatto, P. Fava, I. Stanganelli, S. Ribero +29 more
2023European Journal of Cancer18 citations Open access
Semantic Scholar
TERT Promoter Mutations Differently Correlate with the Clinical Outcome of MAPK Inhibitor-Treated Melanoma Patients
P. Del Bianco, Camilla Stagni, S. Giunco, A. Fabozzi +8 more
2020Cancers18 citations Open access
Semantic Scholar
Neoadjuvant treatment with dabrafenib of unresectable localizations from occult melanoma.
M. Rastrelli, J. Pigozzo, A. di Maggio, A. Tosi +2 more
2014Melanoma research18 citations
Semantic Scholar
Pooled Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone in Patients With Advanced Melanoma
Georgina V. Long, J. Larkin, D. Schadendorf, J. Grob +21 more
2024Journal of Clinical Oncology15 citations
Semantic Scholar
The prognostic impact of the extent of ulceration in patients with clinical stage I–II melanoma: a multicentre study of the Italian Melanoma Intergroup (IMI)
F. Portelli, F. Galli, L. Cattaneo, M. Cossa +25 more
2020British Journal of Dermatology14 citations
Semantic Scholar
Paraneoplastic cerebellar degeneration with anti-Yo antibodies associated with metastatic uveal melanoma.
S. Valpione, M. Zoccarato, R. Parrozzani, J. Pigozzo +4 more
2013Journal of Neurological Sciences14 citations
Semantic Scholar
Sex-related differences in serum biomarker levels predict the activity and efficacy of immune checkpoint inhibitors in advanced melanoma and non-small cell lung cancer patients
G. Pasello, A. Fabricio, P. Del Bianco, V. Salizzato +14 more
2024Journal of Translational Medicine13 citations Open access
Semantic Scholar
Melanoma of Unknown Primary: Evaluation of the Characteristics, Treatment Strategies, Prognostic Factors in a Monocentric Retrospective Study
P. Del Fiore, M. Rastrelli, L. Dall'Olmo, F. Cavallin +20 more
2021Frontiers in Oncology13 citations Open access
Semantic Scholar
Melanoma in Adolescents and Young Adults: Evaluation of the Characteristics, Treatment Strategies, and Prognostic Factors in a Monocentric Retrospective Study
P. Del Fiore, I. Russo, B. Ferrazzi, A. Dal Monico +23 more
2021Frontiers in Oncology12 citations Open access
Semantic Scholar
Initial results from a phase IIIb/IV study evaluating two dosing regimens of nivolumab (NIVO) in combination with ipilimumab (IPI) in patients with advanced melanoma (CheckMate 511).
C. Lebbé, N. Meyer, L. Mortier, I. Márquez-Rodas +13 more
2018Annals of Oncology11 citations Open access
Semantic Scholar
Italian cohort of ipilimumab expanded access programme (EAP): Efficacy, safety, and correlation with mutation status in metastatic melanoma patients.
P. Queirolo, F. Spagnolo, M. Altomonte, V. Chiarion-Sileni +16 more
201311 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

V. Chiarion-Sileni×20
Invite
V. Chiarion-Sileni — researcher profile on SciRah
P. Ascierto×17
Invite
P. Ascierto — researcher profile on SciRah
P. Queirolo×16
Invite
P. Queirolo — researcher profile on SciRah
M. Del Vecchio×12
Invite
M. Del Vecchio — researcher profile on SciRah

×12

Invite

M. Mandalà — researcher profile on SciRah

Invite

M. Guida — researcher profile on SciRah

P. Ferrucci×10

Invite

P. Ferrucci — researcher profile on SciRah

S. Valpione×10

Invite

S. Valpione — researcher profile on SciRah

L. Di Guardo×9

Invite

L. Di Guardo — researcher profile on SciRah

Invite

M. Maio — researcher profile on SciRah

A. D. di Giacomo×8

Invite

A. D. di Giacomo — researcher profile on SciRah

P. Del Bianco×8

Invite

P. Del Bianco — researcher profile on SciRah